echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Under the normalization of collection, the price war on generic drugs opened

    Under the normalization of collection, the price war on generic drugs opened

    • Last Update: 2020-06-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network Industry Dynamic) Recently, the Hebei Provincial Health Insurance Bureau issued the Notice on FurtherIng the Work of Drug Hanging Network (Draft for Comments), announcing that all drugs listed and sold in China shall be registered with the approval of the State Drug Supervision and Administration Department for the purpose of listing and selling in China, and shall solicit opinions from all walks of life on specific rulesaccording to theaccording to the Notice, ten types of drugs eligible can be directly linked to the netIncluding the national negotiation drugs, the state and Hebei with the amount of procurement of drugs, can be directly linked to the market according to the results of the bargaining or the winning price, and the network cycle and negotiation, procurement cycle is consistentFor the shortage of drugs, innovative drugs, can be in accordance with the negotiation stouspen price directly linked to the netit is worth noting that for the application of online enterprises to reach or more than 3 drugs, the need to bid to hang the net, from low to high, to the high price will be eliminated, the elimination rate can be as high as 50%In this regard, the industry generally believed that Hebei Province this issue, not only means that the province will usher in a new round of price-cutting frenzy, will further promote the nationwide generic drug price war intensifiedin fact, since the introduction of the 4 plus 7 drug collection in 2018, the decline in drug prices has exceeded market expectations, the trend of price cuts has already arrivedFor example, at the end of 2019, Jiangsu Pharmaceutical Mining Platform issued a notice stating that it intends to adjust the price of some medicines according to the enterprise's applicationThe scope of adjustment involves 16 clinically common drugs, such as Katopli of Stone Pharmaceutical Group, Yewalcohol albumin of Hengrui Pharmaceuticals, and tofateib, which are sunny, including a decrease of more than 70%April 15, 2020, Hunan's special procurement of antibiotics announced the results of the winning bid, a total of 52 varieties of 154 products won the bidIn addition to some small and medium-sized enterprises, there are national pharmaceutical group, Shanghai pharmaceutical, North China pharmaceutical and other leading enterprises, multinational pharmaceutical enterprises only Bayer won the bidOf the 154 product regulations in which the winning bid was awarded, 93 drugs were priced at 10 yuan per bag/tablet and 25 were priced at 1 yuanShortly after, 18 provincial public medical institutions in Anhui Province formally signed a successful drug confirmation agreement with representatives from 26 pharmaceutical manufacturers, with an average reduction of 35.16% in purchase prices It is reported that the purchase of the cephalosporin , anti-tumor two categories of 35 drugs, including 29 cephalosporin drugs and 6 anti-tumor drugs in addition to , there are more and more actions to expand the range of band procurement with policy support On April 23, the Shandong Provincial Health Insurance Bureau issued a "Notice on the Organization to Fill out part of the Drug Purchase Plan" and announced the start of the province's carry-on procurement A total of 40 varieties of aspirin, nitrobenzene, metorol, fluoroquine, omeprazole, rebeiraquine, compound glyphosate, ranolaquine, and zoaminochloride were selected, of which 27 were injections and 13 were oral, accounting for more than two-thirds of the injections in general, the purpose of collection is in fact from the pilot to expand to gradually normal, and the price of drugs continue to decline The industry believes that in this trend, the generic drug price war is about to start In the face of this kind of industry environment, enterprises must take the road of innovation if they want to have a competitive advantage And innovation does not just focus on drug innovation, marketing innovation is also the area that needs to be focused and laid out.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.